Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nanobiotix S.A. filings document foreign private issuer reporting for a late-stage clinical biotechnology company developing nanoparticle-based therapeutic platforms. Recent Form 6-K reports furnish press-release exhibits covering JNJ-1900 (NBTXR3) clinical and regulatory disclosures, Nanoprimer preclinical data, operating and financial updates, and responses to corporate-status speculation.
The filing record also documents capital-structure and governance information, including share capital, theoretical and exercisable voting rights reported under French market rules, material agreements tied to development and commercialization collaborations, and foreign private issuer status on Form 20-F for its Euronext Paris and Nasdaq-listed securities.